drugset
drugset / Trial / NCT07000955

Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe Obesity

NCT07000955 ↗

Phase 1/2 Active not recruiting 98 enrolled Innovent Biologics (Suzhou) Co. Ltd.
RandomizedParallel-groupTriple-blindTreatment

Summary

This study is a multicenter, randomized, partially double-blind (double-blind in both the IBI362 group and the placebo group, with the tirbopeptide group open), placebo and active drug controlled design study

Timeline

Start
2025-06-17
Primary completion
2026-09-30
Completion
2027-05-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Mazdutide Protein / enzyme biologic 2 mg Subcutaneous
Subject Mazdutide Protein / enzyme biologic 12 mg Subcutaneous
Subject Mazdutide Protein / enzyme biologic 15 mg Subcutaneous
Comparator Tirzepatide Peptide 2.5 mg Subcutaneous
Comparator Tirzepatide Peptide 15 mg Subcutaneous

Indications

obesity disorder